top of page

Intercept’s new PBC liver disease treatment yields successful clinical trials

Intercept Pharmaceuticals’ phase III trial of ocaliva(obeticholic acid) met its primary endpoint for the treatment of patients with primary biliary cholangitis, formerly known as primary biliary cirrhosis (PBC), and improved multiple biochemical disease markers as compared to placebo with high statistical significance.

Click on this link for more information.



Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page